- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03706235
Colvera for Detection of Disease Recurrence (NOVA)
July 13, 2020 updated by: Clinical Genomics Pathology
Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed With Colorectal Cancer- "NOVA"
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an observational, prospective comparison study, where blood is collected for assay of methylated BCAT1 and IKZF1 DNA and CEA, from subjects who have undergone curative treatment for primary CRC of stages II and III (AJCC) and who are in remission and scheduled for follow-up radiological imaging as part of their surveillance program for recurrence.
Participation is for one visit only as part of each subject's surveillance-monitoring schedule.
Two K2-EDTA blood tubes and two PAXgene™ tubes will be collected Any evidence of methylated BCAT1 and/or IKZF1 DNA in blood represents a Colvera "positive" result.
CEA levels of 5ug/L or higher will represent a "positive" result.
Sensitivity and specificity of the Colvera and CEA test will be estimated and compared in a paired fashion in each case where recurrence status has been investigated and determined by the site clinical management team.
Blood testing shall be performed and analyzed by qualified staff blinded to clinical status.
This is a cross-sectional observational non-significant risk study, and test results will not be used for clinical management, i.e. there will be no interventions in subjects consenting to participate in this Research Study.
Study Type
Observational
Enrollment (Actual)
488
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Redondo Beach, California, United States, 90277
- Torrance Memorial Physician Network
-
-
Delaware
-
Dover, Delaware, United States, 19901
- Bayhealth
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Evanston, Illinois, United States, 60201
- NorthShore Health System
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Louisiana
-
Metairie, Louisiana, United States, 70001
- Colon and Rectal Surgery Associates
-
-
Michigan
-
Novi, Michigan, United States, 48374
- Providence Hospital-Ascension Health
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute-Allina Health
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- Essex Oncology
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
subjects who have undergone curative treatment for primary Colon or rectal cancer of stages II and III (AJCC), and who are in remission and scheduled for clinical follow-up (usually radiological imaging) as part of their surveillance program for recurrence.
Description
Inclusion Criteria:
- Subject is 18 years or older, and capable and willing to provide informed consent.
- Subject has undergone curative treatment for primary CRC of stages II and III (AJCC).
- Subject has no clinical evidence of disease (NED) (after initial treatment)
- Subject has concluded course of initial treatment for primary CRC (i.e. end of surgery, chemotherapy and/or radiotherapy)
- Subject is willing/able to provide a blood sample
Exclusion Criteria:
- Subject has evidence of residual disease.
- Subject has other organ cancer at the time of recruitment.
- Subject has prior history of recurrent CRC.
- Subject has concurrent serious non-neoplastic illness that makes enrollment impractical or clinically inappropriate.
- Subject is receiving chemo- or radiotherapy at the time of blood collection, or between blood collection and radiological imaging.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
No recurrence
Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g.
ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging.
Imaging documents no recurrence.
|
Draw 40 mls of blood from eligible subjects.
Process and ship samples to sponsor.
|
|
Recurrence
Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g.
ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence.
Imaging documents recurrence.
|
Draw 40 mls of blood from eligible subjects.
Process and ship samples to sponsor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity, specificity, positive predictive value and negative predictive value
Time Frame: 1.5 years
|
on positive or negative Colvera and CEA test results
|
1.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2018
Primary Completion (Actual)
August 16, 2019
Study Completion (Actual)
April 29, 2020
Study Registration Dates
First Submitted
October 11, 2018
First Submitted That Met QC Criteria
October 11, 2018
First Posted (Actual)
October 15, 2018
Study Record Updates
Last Update Posted (Actual)
July 14, 2020
Last Update Submitted That Met QC Criteria
July 13, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CG001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The data collected by recruiting sites is captured without any PHI or identifiers in an Electronic Data Capture system managed for the sponsor by a CRO.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.